Acadia Pharmaceuticals (ACAD) came out with fourth-quarter earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago.
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
ACADIA Pharmaceuticals reported its fourth quarter results this week and provided initial guidance for FY2025, highlighting key financial metrics and future projections. The company continues to see solid growth from its two products on the market and has also build up a large amount of net cash on its balance sheet. ACADIA Pharmaceuticals is also advancing several key assets within its developmental pipeline.
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q4 2024 Results Conference Call February 26, 2025 4:30 PM ET Company Participants Al Kildani - SVP of Investor Relations & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP, Head of R&D Mark Schneyer - EVP, CFO Conference Call Participants Ami Fadia - Needham & Company Tessa Romero - JPMorgan Joel Beatty - Baird Tazeen Ahmad - Bank of America Securities Gregory Renza - RBC Capital Markets Charles Duncan - Cantor Sumant Kulkarni - Canaccord Genuity LLC Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Shannon, and I will be your coordinator for today.
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago.
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
We have just released a list of 10 companies that are expected to finish 2024 on a strong note with significant gains. In this article, we will examine how ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) compares to these other firms. The last trading day of the year saw a lack of excitement on Wall Street.